• 1
    Lake RA, Robinson BWS. Immunotherapy and chemotherapy – a practical partnership. Nat Rev Cancer 2005; 5: 397405.
  • 2
    Baird RD, Kaye SB. Drug resistance reversal—are we getting closer? Eur J Cancer 2003; 39: 245061.
  • 3
    Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Shmits R, Unterhalt M. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone—results of a prospective randomized study of the german low grade lymphoma study group (GLSG). Blood 2005; 106: 372532.
  • 4
    Terando A, Mule JJ. On combining antineoplastic drugs with tumor vaccines. Cancer Immunol Immunother 2003; 52: 6805.
  • 5
    Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 50729.
  • 6
    Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T Cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 521118.
  • 7
    Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 2002; 123: 16874.
  • 8
    Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 73441.
  • 9
    Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo. Prostate 2004; 62: 16586.
  • 10
    Singh TR, Shanker S, Chen X, Asim M, Srivastava RK. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and the regression of breast carcinoma in vivo. Cancer Res 2003; 63: 5390400.
  • 11
    Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4: 2317.
  • 12
    Brutkiewicz RR, Sriram V. Natural killer T (NKT) cells and their role in antitumor immunity. Crit Rev Oncol Hematol 2002; 41: 28798.
  • 13
    Smyth MJ, Crowe NY, Hayakawa Y, Takeda K, Yagita H, Godfrey DI. NKT cells—conductors of tumor immunity? Curr Opin Immunol 2002; 14: 16571.
  • 14
    Swann J, Crowe NY, Hayakawa Y, Godfrey DI, Smyth MJ. Regulation of antitumour immunity by CD1d-restricted NKT cells. Immunol Cell Biol 2004; 82: 32331.
  • 15
    Nieda M, Nicol A, Koezuka Y, Kikuchi A, Lapteva N, Tanaka Y, Tokunaga K, Suzuki K, Kayagaki N, Yagita H, Hirai H, Juji T. TRAIL expression by activated human CD4+Vα24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood 2001; 97: 206774.
  • 16
    Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, Durrant S, Juji T. Human invariant vα24+ natural killer T cells activated by α-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology 2000; 99: 22934.
  • 17
    Thomas SY, Hou R, Boyson JE, Means TK, Hess C, Olson DP, Luster AD. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells. J Immunol 2003; 171: 257180.
  • 18
    Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003; 17: 106877.
  • 19
    Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996; 156: 367886.
  • 20
    Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, Yagita H. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999; 162: 263947.
  • 21
    Nishi N, van der Vliet HJ, Koezuka Y, von Blomberg BM, Scheper RJ, Pinedo HM, Giaccone G. Synergistic effect of KRN7000 with interleukin-15, -7, and -2 on the expansion of human V α24+V β11+ T cells in vitro. Hum Immunol 2000; 61: 35765.
  • 22
    van der Vliet HJ, Nishi N, Koezuka Y, von Blomberg BM, van den Eertwegh AJ, Porcelli SA, Pinedo HM, Scheper RJ, Giaccone G. Potent expansion of human natural killer T cells using α-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J Immunol Methods 2001; 247(1/2): 6172.
  • 23
    Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumour escape. Nat Immunol 2002; 3: 9918.
  • 24
    O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 223546.
  • 25
    Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 66675.
  • 26
    Fuji N, Ueda Y, Fujiwara H, Toh T, Yoshimura T, Yamagishi H. Antitumor effect of α-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver. Clin Cancer Res 2000; 6: 33807.
  • 27
    Hagihara M, Gansuvd B, Ueda Y, Tsuchiya T, Masui A, Tazume K, Inoue H, Kato S, Hotta T. Killing activity of human umbilical cord blood-derived TCRVα24(+) NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells. Cancer Immunol Immunother 2002; 51(1): 18.
  • 28
    Kikuchi A, Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, Tadokoro K, Durrant S, Boyd A, Juji T, Nicol A. In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+ NKT cells against melanoma. Br J Cancer 2001; 85: 7416.
  • 29
    Metelitsa LS, Naidenko OV, Kant A, Wu HW, Loza MJ, Perussia B, Kronenberg M, Seeger RC. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J Immunol 2001; 167: 311422.
  • 30
    Kamesaki H. Mechanisms involved in chemotherapy-induced apoptosis and their implications in cancer chemotherapy. Int J Hematol 1998; 68: 2943.
  • 31
    Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res 2002; 85: 14574.
  • 32
    McDermott U, Longley DB, Galligan L, Allen W, Wilson T, Johnston PG. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res 2005; 65: 895160.
  • 33
    Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int J Cancer 2002; 99: 491504.
  • 34
    Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL-induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002; 1: 5207.
  • 35
    Ng CP, Zisman A, Bonavida B. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. Prostate 2002; 53: 28699.
  • 36
    Takahashi T, Nieda M, Koezuka Y, Nicol A, Porcelli SA, Ishikawa Y, Tadokoro K, Hirai H, Juji T. Analysis of human V α24+ CD4+ NKT cells activated by α-glycosylceramide-pulsed monocyte-derived dendritic cells. J Immunol 2000; 164: 445864.
  • 37
    Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis or tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002; 62: 617886.
  • 38
    Gumperz JE, Miyake S, Yamamura T, Brenner MB. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J Exp Med 2002; 195: 62536.
  • 39
    Vivier E, Tomasello E, Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr Opin Immunol 2002; 14: 30611.
  • 40
    Takahashi T, Haraguchi K, Chiba S, Yasukawa M, Shibata Y, Hirai H. Vα24+ natural killer T-cell responses against T-acute lymphoblastic leukaemia cells: implications for immunotherapy. Br J Haematol 2003; 122: 2319.
  • 41
    Konishi J, Yamazaki K, Yokouchi H, Shinagawa N, Iwabuchi K, Nishimura M. The characteristics of human NKT cells in lung cancer—CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients. Hum Immunol 2004; 65: 137788.
  • 42
    Stremmel C, Exley M, Balk S, Hohenberger W, Kuchroo VK. Characterization of the phenotype and function of CD8(+),α/β(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets. Eur J Immunol 2001; 31: 281828.
  • 43
    Mattarollo SR, Lin H, Nicol AJ. In vitro activation and expansion of human Vα24/Vβ11 NKT cells and CD3-CD56+ NK cells for therapy of human malignancy. Immunology. 2004; 16570. Supplement, 12th International Congress of Immunology and 4th Annual Conference of FOCIS.
  • 44
    Berry WR. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Urology 2005; 56(6 Suppl ): 27.
  • 45
    Rosenberg JE, Small EJ. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clin Prostate Cancer 2004; 3: 1224.
  • 46
    Markiewicz MA, Kast WM. Advances in immunotherapy for prostate cancer. Adv Cancer Res 2003; 87: 15994.
  • 47
    Harada M, Noguchi M, Itoh K. Target molecules in specific immunotherapy against prostate cancer. Int J Clin Oncol 2003; 8: 1939.
  • 48
    Fong L, Small EJ. Immunotherapy for prostate cancer. Semin Oncol 2003; 30: 64958.